Nature Communications (Feb 2023)
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer
- Lingzhi Hong,
- Muhammad Aminu,
- Shenduo Li,
- Xuetao Lu,
- Milena Petranovic,
- Maliazurina B. Saad,
- Pingjun Chen,
- Kang Qin,
- Susan Varghese,
- Waree Rinsurongkawong,
- Vadeerat Rinsurongkawong,
- Amy Spelman,
- Yasir Y. Elamin,
- Marcelo V. Negrao,
- Ferdinandos Skoulidis,
- Carl M. Gay,
- Tina Cascone,
- Saumil J. Gandhi,
- Steven H. Lin,
- Percy P. Lee,
- Brett W. Carter,
- Carol C. Wu,
- Mara B. Antonoff,
- Boris Sepesi,
- Jeff Lewis,
- Don L. Gibbons,
- Ara A. Vaporciyan,
- Xiuning Le,
- J. Jack Lee,
- Sinchita Roy-Chowdhuri,
- Mark J. Routbort,
- Justin F. Gainor,
- John V. Heymach,
- Yanyan Lou,
- Jia Wu,
- Jianjun Zhang,
- Natalie I. Vokes
Affiliations
- Lingzhi Hong
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Muhammad Aminu
- Department of Imaging Physics, The University of Texas MD Anderson Cancer Center
- Shenduo Li
- Division of Hematology and Oncology, Mayo Clinic
- Xuetao Lu
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center
- Milena Petranovic
- Department of Radiology, Massachusetts General Hospital
- Maliazurina B. Saad
- Department of Imaging Physics, The University of Texas MD Anderson Cancer Center
- Pingjun Chen
- Department of Imaging Physics, The University of Texas MD Anderson Cancer Center
- Kang Qin
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Susan Varghese
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Waree Rinsurongkawong
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center
- Vadeerat Rinsurongkawong
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center
- Amy Spelman
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Yasir Y. Elamin
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Marcelo V. Negrao
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Ferdinandos Skoulidis
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Carl M. Gay
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Tina Cascone
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Saumil J. Gandhi
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center
- Steven H. Lin
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center
- Percy P. Lee
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center
- Brett W. Carter
- Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center
- Carol C. Wu
- Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center
- Mara B. Antonoff
- Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center
- Boris Sepesi
- Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center
- Jeff Lewis
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center
- Don L. Gibbons
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Ara A. Vaporciyan
- Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center
- Xiuning Le
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- J. Jack Lee
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center
- Sinchita Roy-Chowdhuri
- Department of Pathology, The University of Texas MD Anderson Cancer Center
- Mark J. Routbort
- Department of Pathology, The University of Texas MD Anderson Cancer Center
- Justin F. Gainor
- Department of Medicine, Massachusetts General Hospital
- John V. Heymach
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Yanyan Lou
- Division of Hematology and Oncology, Mayo Clinic
- Jia Wu
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Jianjun Zhang
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- Natalie I. Vokes
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-023-36328-z
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 15
Abstract
Immune checkpoint inhibitors with or without chemotherapy are now standard of care for non-small cell lung cancer. However, the benefits of combination vs sequential therapy have not been fully explored. Here, the authors analysed 1,133 patient records and show combination therapy showed increased protection against early progression, but similar overall survival.
